Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence - Archive ouverte HAL Access content directly
Journal Articles Frontiers in Pharmacology Year : 2020

Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence

, (1) ,
1
Jean Barré
  • Function : Author
Jean-Marc Sabatier
Cédric Annweiler

Abstract

With the lack of effective therapy, chemoprevention and vaccination, focusing on the immediate repurposing of existing drugs gives hope of curbing the pandemic. Interestingly, montelukast, a drug usually used in asthma, may be proposed as a potential adjuvant therapy in COVID-19. The aim of the present article was to review the properties of montelukast that could be beneficial in COVID-19. Ten experimentally supported properties were retrieved, either related to SARS-CoV-2 (antiviral properties, prevention of endotheliitis and of neurological disorders linked to SARS-CoV-2), and/or related to the host (improvement of atherogenic vascular inflammation, limitation of the ischemia/reperfusion phenomenon, improvement of respiratory symptoms), and/or related to serious COVID-19 outcomes (limitation of the cytokine storm, mitigation of acute respiratory distress syndrome), and/or related to tissue sequelae (antioxidant properties, anti-fibrosis effects). Based on gathered theoretical evidence, we argue that montelukast should be further tested to prevent and treat COVID-19 outcomes.

Dates and versions

hal-03170739 , version 1 (16-03-2021)

Identifiers

Cite

Jean Barré, Jean-Marc Sabatier, Cédric Annweiler. Montelukast Drug May Improve COVID-19 Prognosis: A Review of Evidence. Frontiers in Pharmacology, 2020, 11, pp.1344. ⟨10.3389/fphar.2020.01344⟩. ⟨hal-03170739⟩
239 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More